SNTI - Senti Bio Debt to Book Capitalization Ratio

Senti Biosciences, Inc. (SNTI) focuses on creating programmable gene circuits for the targeted elimination of tumors. A robust R&D foundation in synthetic biology provides significant leadership potential. Recession resilience is guaranteed by a sovereign drug development cycle. This debt-to-equity chart demonstrates current credit risk, where the 0.00 level captures the company's latest financial leverage values.

SNTI Senti Bio: Debt to Book Capitalization Ratio in the range 04/28/2023 - 10/27/2026

Summary analytical data breakdowns for sentibio.com (SNTI)

- price and consensus price forecast:

Stock Price Senti Biosciences|SNTI - Consensus Target

- market capitalization data:

Market Value SNTI|SNTI - Total Enterprise Value

- book capitalization data:

Net Assets per Single Share Senti Biosciences|SNTI - Company Book Value|Market Value to Book Value Ratio sentibio.com|SNTI - Company Assets

- debt and liquidity data:

Total Debt to Capital Senti Biosciences, Inc.|SNTI - Long-Term Indebtedness to Equity|Short-Term Debt to Equity Ratio Senti Biosciences|SNTI - Company Cumulative Debt|Debt to Book Value SNTI

Analysis of all company metrics:SNTI, Senti Biosciences Inc

The total liabilities-to-equity ratio determines the issuer's dependence on borrowed funds and its resilience to default. The current value of 0.00 demonstrates the business's actual margin of safety. By analyzing the company's balance sheet financial leverage, an investor assesses the ability of Senti Biosciences, Inc. (SNTI) to finance complex biocomponent supply chains. Diversification of production bases reduces operational risks. The downward trend of this metric confirms the long-term financial stability of the capital.

Competitors of Senti Biosciences, Inc.